Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants

Update Il y a 4 ans
Reference: EUCTR2008-001457-18

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the immunogenicity of 60 ?g, 120 µg and 200 ?g of rLP2086 as measured by serum bactericidal assay (SBA) to MnB strains expressing LP2086 subfamily A and B proteins in healthy infants 1 month after the infant series.


Inclusion criteria

  • Healthy infant vaccination against Meningitis B

Links